PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer

NCT00589550 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped low accrual

Conditions

Kidney Cancer

Interventions

BIOLOGICAL: PEG-interferon alfa-2b
DRUG: Sorafenib
GENETIC: gene expression analysis
GENETIC: polymerase chain reaction
GENETIC: reverse transcriptase-polymerase chain reaction
OTHER: flow cytometry
OTHER: immunoenzyme technique
OTHER: laboratory biomarker analysis

Sponsor

Thomas Olencki

Collaborators

[object Object]